OpenURL Connection Search

Select item for more details and to access through your institution.

The evolving role of Alemtuzumab in management of patients with CLL.
Published in:
Leukemia (08876924), 2005, v. 19, n. 12, p. 2147, doi. 10.1038/sj.leu.2403984
By:
- Faderl, S.;
- Coutré, S.;
- Byrd, J.C.;
- Dearden, C.;
- Denes, A.;
- Dyer, M.J.S.;
- Gregory, S.A.;
- Gribben, J.G.;
- Hillmen, P.;
- Keating, M.;
- Rosen, S.;
- Venugopal, P.;
- Rai, K.
Publication type:
Article
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.
Published in:
Leukemia (08876924), 2004, v. 18, n. 7, p. 1207, doi. 10.1038/sj.leu.2403388
By:
- Lucas, D.M.;
- Davis, M.E.;
- Parthun, M.R.;
- Mone, A.P.;
- Kitada, S.;
- Cunningham, K.D.;
- Flax, E.L.;
- Wickham, J.;
- Reed, J.C.;
- Byrd, J.C.;
- Grever, M.R.
Publication type:
Article
Acalabrutinib With Obinutuzumab in Treatment‐Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3‐Year Follow‐Up.
Published in:
Hematological Oncology, 2019, v. 37, p. 209, doi. 10.1002/hon.26_2630
By:
- Woyach, J.;
- Rogers, K.A.;
- Bhat, S.;
- Blachly, J.;
- Jianfar, M.;
- Hamdy, A.;
- Frigault, M.M.;
- Izumi, R.;
- Munugalavadla, V.;
- Quah, C.S.;
- Wang, M.H.;
- Byrd, J.C.
Publication type:
Article
Acalabrutinib With Obinutuzumab in Treatment‐Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3‐Year Follow‐Up.
Published in:
Hematological Oncology, 2019, v. 37, p. 209, doi. 10.1002/hon.26_2630
By:
- Woyach, J.;
- Rogers, K.A.;
- Bhat, S.;
- Blachly, J.;
- Jianfar, M.;
- Hamdy, A.;
- Frigault, M.M.;
- Izumi, R.;
- Munugalavadla, V.;
- Quah, C.S.;
- Wang, M.H.;
- Byrd, J.C.
Publication type:
Article
INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS.
Published in:
Hematological Oncology, 2017, v. 35, p. 109, doi. 10.1002/hon.2437_99
By:
- Kipps, T.J.;
- Fraser, G.;
- Coutre, S.E.;
- Brown, J.R.;
- Barrientos, J.C.;
- Barr, P.M.;
- Byrd, J.C.;
- O'Brien, S.M.;
- Dilhuydy, M.;
- Hillmen, P.;
- Jaeger, U.;
- Moreno, C.;
- Cramer, P.;
- Stilgenbauer, S.;
- Chanan ‐ Khan, A.A.;
- Mahler, M.;
- Salman, M.;
- Cheng, M.;
- Londhe, A.;
- Ninomoto, J.
Publication type:
Article
EFFECT OF SINGLE-AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
Published in:
Hematological Oncology, 2017, v. 35, p. 233, doi. 10.1002/hon.2438_96
By:
- Tam, C.S.;
- Byrd, J.C.;
- O'Brien, S.;
- Coutre, S.;
- Barr, P.M.;
- Furman, R.R.;
- Kipps, T.J.;
- Burger, J.A.;
- Stevens, D.;
- Sharman, J.;
- Ghia, P.;
- Flinn, I.;
- Zhou, C.;
- Ninomoto, J.;
- James, D.F.;
- Wierda, W.G.
Publication type:
Article
LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP.
Published in:
Hematological Oncology, 2017, v. 35, p. 235, doi. 10.1002/hon.2438_98
By:
- Montillo, M.;
- Byrd, J.C.;
- Hillmen, P.;
- O'Brien, S.;
- Barrientos, J.C.;
- Reddy, N.M.;
- Coutre, S.;
- Tam, C.S.;
- Mulligan, S.P.;
- Jaeger, U.;
- Barr, P.M.;
- Furman, R.R.;
- Kipps, T.J.;
- Thornton, P.;
- Moreno, C.;
- Pagel, J.M.;
- Burger, J.A.;
- Jones, J.;
- Dai, S.;
- Vezan, R.
Publication type:
Article

Found: 7

The evolving role of Alemtuzumab in management of patients with CLL.

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.

Acalabrutinib With Obinutuzumab in Treatment‐Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3‐Year Follow‐Up.

Acalabrutinib With Obinutuzumab in Treatment‐Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3‐Year Follow‐Up.

INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS.

EFFECT OF SINGLE-AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).

LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP.